2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAlopeciaBreast NeoplasmsCyclin-Dependent Kinase 4FemaleHumansMinoxidilRetrospective StudiesTreatment OutcomeConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore grade
2021
Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use
Amigo M, Hoffman K, Chung C, Lustberg M, Wesolowski R, VanDeusen J, Stover D, Suarez GT, Cherian M, Kaffenberger B, Dulmage B. Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use. Journal Of The American Academy Of Dermatology 2021, 86: 1346-1348. PMID: 33961922, DOI: 10.1016/j.jaad.2021.04.092.Peer-Reviewed Original ResearchCell Cycle ProteinsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase Inhibitor p16Enzyme InhibitorsHumans